Search Results
Feb 11, 2026, 01:36 ET Flex LNG - Fourth Quarter 2025 Earnings Release
https://news.cision.com/flex-lng/r/flex-lng---fourth-quarter-2025-earnings-release,c4305680The following files are available for download:
More news about: Flex LNG
Feb 11, 2026, 01:34 ET Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
(344.3) R&D expenses (74.4)
More news about: Hansa Biopharma AB
Feb 11, 2026, 01:32 ET Vizzio Technologies Strengthens Leadership As Global Growth Accelerates
surveillance space. Since entering the camera market just in 2025, the company has already made a significant impact with its AI‑driven solutions. The R&D pipeline is equally compelling – from cameras on robot dogs to sensors on drones and other autonomous platforms, the possibilities for intelligent,
More news about: Vizzio Technologies
Feb 11, 2026, 01:29 ET Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
(344.3) R&D expenses (74.4)
More news about: Hansa Biopharma AB
Feb 11, 2026, 01:24 ET Kojamo plc's Financial Statements Release 1 January-31 December 2025
https://news.cision.com/kojamo-oyj/r/kojamo-plc-s-financial-statements-release-1-january-31-december-2025,c4305706The following files are available for download:
More news about: Kojamo Oyj
Feb 11, 2026, 01:19 ET Arctic Therapeutics Announces Enrollment of First Patients in Phase IIa Trial of AT-004 for Acne Vulgaris
https://news.cision.com/arctic-therapeutics/r/arctic-therapeutics-announces-enrollment-of-first-patients-in-phase-iia-trial-of-at-004-for-acne-vul,c4305375The following files are available for download:
More news about: Arctic Therapeutics
Feb 11, 2026, 01:14 ET Arctic Therapeutics Announces Enrollment of First Patients in Phase IIa Trial of AT-004 for Acne Vulgaris
https://news.cision.com/arctic-therapeutics/r/arctic-therapeutics-announces-enrollment-of-first-patients-in-phase-iia-trial-of-at-004-for-acne-vul,c4305375The following files are available for download:
More news about: Arctic Therapeutics
Feb 11, 2026, 00:42 ET Fourth Quarter 2025 Results and Strategy Update
https://news.cision.com/aker-bp-asa/r/fourth-quarter-2025-results-and-strategy-update,c4305628The following files are available for download:
More news about: Aker BP ASA
Feb 11, 2026, 00:30 ET Artmarket.com: Q4 and annual revenue growth; Gemini 3 Pro Deep Think audit of Artprice; The Art Market recovers with +12% turnover; AI set to dominate the Art Market in 2026
train and test complex inference models locally, without waiting for shared cloud resources to become available. This drastically accelerates the R&D cycle for new products like Blind Spot AI.2. Total Confidentiality (Privacy-First): highly sensitive data (private collection inventories,
More news about: Artmarket.com
Feb 11, 2026, 00:30 ET Artmarket.com: Q4 and annual revenue growth; Gemini 3 Pro Deep Think audit of Artprice; The Art Market recovers with +12% turnover; AI set to dominate the Art Market in 2026
train and test complex inference models locally, without waiting for shared cloud resources to become available. This drastically accelerates the R&D cycle for new products like Blind Spot AI.2. Total Confidentiality (Privacy-First): highly sensitive data (private collection inventories,
More news about: Artmarket.com
Feb 10, 2026, 23:03 ET Honda Motor Co., Ltd. (HMC:NYSE) announced its consolidated financial results for the fiscal third quarter ended December 31, 2025.
business, the impact of tariffs as well as one time expenses related to EVs resulted in a decrease in profits.Operating cash flows after R&D adjustment 1,855.8 bil. yenFYE March 31, 2026 Financial ForecastOperating Profit 550.0 bil. yen
More news about: American Honda Motor Co., Inc.
Feb 10, 2026, 18:15 ET /C O R R E C T I O N -- PremierOne Credit Union/
More news about: PremierOne Credit Union
Feb 10, 2026, 18:15 ET 歌禮選定口服胰澱素受體激動劑多肽ASC36進行臨床開發
Platform，ULAP）技術以及口服多肽遞送增強技術（Peptide Oral Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款在研小分子GLP-1R激動劑，既可每日一次口服也可每月一次至每季度一次皮下注射作為減重治療療法和減重維持療法，用於長期體重管理；ASC36，一款胰澱素受體激動劑多肽，ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽，ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲了解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Feb 10, 2026, 18:15 ET Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual
More news about: Ascletis Pharma Inc.
Feb 10, 2026, 17:31 ET PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight
(Dialectic Therapeutics), and others, along with increasing applicability in neurodegenerative and inflammatory diseases, are further fueling sustained R&D investment.LAS VEGAS, Feb. 10, 2026 /PRNewswire/ -- DelveInsight's
More news about: DelveInsight Business Research LLP
Feb 10, 2026, 16:23 ET Teradata Advances Board Refreshment Program
HyperlinkLisa R. Bacus75,104
More news about: Teradata Corporation
Feb 10, 2026, 16:00 ET Antigen Carriage Associated with Lamotrigine-Induced DRESS
(SNP2HLA). Case-control (matched 10:1) HLA association studies were performed at the locus, haplotype and amino acid levels using midasHLA (version 1.14.0), R (version 4.4.1), reported OR, 95% CI and Bonferroni correction for P values (Pc).The researchers identified 30 lamotrigine-induced DRESS cases
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 10, 2026, 15:12 ET Linglong Tire Winter Experience 2026 in Österreich
verschiedenen Parcours unter Beweis stellen.Alle Fahrzeuge waren mit dem neuesten Linglong Sport-Master-Winterreifenprofil in der Größe 225/40 R18 92W ausgestattet – dem ersten Linglong-Reifen, der in Deutschland entwickelt und exklusiv in Europa produziert wurde. Im vergangenen Herbst erhielt
More news about: Shandong Linglong Tyre Co., Ltd.
Feb 10, 2026, 14:46 ET /C O R R E C T I O N -- Biglari Capital Corp./
More news about: Biglari Capital Corp.
Feb 10, 2026, 14:28 ET Insider Information: Kojamo has agreed to acquire a housing portfolio and issued special rights entitling to shares
https://news.cision.com/kojamo-oyj/r/insider-information--kojamo-has-agreed-to-acquire-a-housing-portfolio-and-issued-special-rights-enti,c4305634
More news about: Kojamo Oyj